Overview of strategies for addressing BRIs in drug discovery: Impact on optimization and design
- 30 June 2011
- journal article
- review article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 192 (1-2) , 56-59
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Structural Alerts, Reactive Metabolites, and Protein Covalent Binding: How Reliable Are These Attributes as Predictors of Drug Toxicity?Chemistry & Biodiversity, 2009
- Approaches for Minimizing Metabolic Activation of New Drug Candidates in Drug Discovery2009
- Cytochrome P450 and Chemical ToxicologyChemical Research in Toxicology, 2007
- Metabolism and Toxicity of Drugs. Two Decades of Progress in Industrial Drug MetabolismChemical Research in Toxicology, 2007
- Applying Mechanisms of Chemical Toxicity to Predict Drug SafetyChemical Research in Toxicology, 2007
- Reactive Intermediates and the Pathogenesis of Adverse Drug Reactions: The Toxicology PerspectiveCurrent Drug Metabolism, 2006
- Addressing Metabolic Activation as an Integral Component of Drug DesignDrug Metabolism Reviews, 2006
- Generation of reactive intermediatesJournal of Biochemical and Molecular Toxicology, 2005
- Role of Metabolism in Drug-Induced Idiosyncratic HepatotoxicityCritical Reviews in Toxicology, 2005
- Screening for the potential of a drug candidate to cause idiosyncratic drug reactionsDrug Discovery Today, 2003